PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells

Oncotarget

Volumn 7, Issue 23, 2016, Pages 34190-34200

  Wu, Yan ^a   Yao, Xiaoyuan ^b   Zhu, Miaolin ^a   Qian, Hai ^a   Jiang, Lu ^a   Lan, Ting ^a   Wu, Min ^a   Pang, Ji ^a   Chen, Yongchang ^a  

^a JIANGSU UNIVERSITY   (China)

^b Changchun Medical College   (China)

Author keywords

C Met; Gastric cancer cell; Inhibition; Phosphorylation; Type II cGMP dependent protein kinase G

Indexed keywords

ALANINE; ASPARTIC ACID; CYCLIC GMP DEPENDENT PROTEIN KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE; SOMATOMEDIN C RECEPTOR; THREONINE; VASCULOTROPIN RECEPTOR; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN; PRKG2 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE II; HEPATOCYTE GROWTH FACTOR; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84973662304     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9074     Document Type: Article

References (40)

1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014; 50:1330-1344.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Zhu C, Xu J, Li M, Zhao G, Cao H. Heterogeneity of c-Met expression in Chinese gastric cancer patients. Hum Pathol. 2015; 46:1901-1907.
4. Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. c-Met targeting in advanced gastric cancer: An open challenge. Cancer Lett. 2015; 365:30-36.
5. Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2016; 19:183-191.
6. Noguchi E, Saito N, Kobayashi M, Kameoka S. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 2015; 11:3423-3431.
7. Saito T, Nakanishi H, Mochizuki Y, Ito S, Ito Y, Misawa K, Yatabe Y, Yamamichi K, Kondo E. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. Gastric Cancer. 2015; 18:711-719.
8. Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer. 2012; 15:252-264.
9. Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res. 2012; 35:595-604.
10. Garajova I, Giovannetti E, Biasco G, Peters GJ. c-Met as a Target for Personalized Therapy. Transl Oncogenomics. 2015; 7:13-31.
11. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12:89-103.
12. Rickert KW, Patel SB, Allison TJ, Byrne NJ, Darke PL, Ford RE, Guerin DJ, Hall DL, Kornienko M, Lu J, Munshi SK, Reid JC, Shipman JM, et al. Structural basis for selective small molecule kinase inhibition of activated c-Met. J Biol Chem. 2011; 286:11218-11225.
13. Kadoyama K, Funakoshi H, Ohya-Shimada W, Nakamura T, Matsumoto K, Matsuyama S, Nakamura T. Diseasedependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS. Neurosci Res. 2009; 65:194-200.
14. Hashigasako A, Machide M, Nakamura T, Matsumoto K, Nakamura T. Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J Biol Chem. 2004; 279:26445-26452.
15. Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, Zhu W. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT, MET/ErbB3/MAPK. PLoS One. 2013; 8:e78086.
16. Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015; 17:52.
17. Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T. C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS One. 2013; 8:e79137.
18. Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, Ganapathy V, Browning D. An anti-tumor role for cGMPdependent protein kinase. Cancer Lett. 2006; 240:60-68.
19. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem. 2005; 280:1-4.
20. Jiang L, Lan T, Chen Y, Sang J, Li Y, Wu M, Tao Y, Wang Y, Qian H, Gu L. PKG II inhibits EGF/EGFRinduced migration of gastric cancer cells. PLoS One. 2013; 8:e61674.
21. Lan T, Chen Y, Sang J, Wu Y, Wang Y, Jiang L, Tao Y. Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells. Oncol Rep. 2012; 27:2039-2044.
22. Wu Y, Chen Y, Qu R, Lan T, Sang J. Type II cGMPdependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells. Oncol Rep. 2012; 27:553-558.
23. Wu M, Chen Y, Jiang L, Li Y, Lan T, Wang Y, Qian H. Type II cGMP-dependent protein kinase inhibits epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt signal transduction in gastric cancer cells. Oncol Lett. 2013; 6:1723-1728.
24. Jiang L, Chen Y, Sang J, Li Y, Lan T, Wang Y, Tao Y, Qian H. Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells. Biomed Rep. 2013; 1:399-404.
25. Regad T. Targeting RTK Signaling Pathways in Cancer. Cancers (Basel). 2015; 7:1758-1784.
26. Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G. Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci 2014; 11:23-36.
27. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4:915-925.
28. Sakamoto N, Naito Y, Oue N, Sentani K, Uraoka N, Zarni Oo H, Yanagihara K, Aoyagi K, Sasaki H, Yasui W. MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis. Cancer Sci. 2014; 105:236-243.
29. Li H, Hong Z-H. Mitochondrial DNA mutations in human tumor cells (Review). Oncol Lett. 2012; 4:868-872.
30. MacManus JP, Linnik MD. Gene expression induced by cerebral ischemia: an apoptotic perspective. J Cereb Blood F Met. 1997; 17:815-832.
31. Faria C, Smith C, Rutka J. The Role of HGF/c-Met Pathway Signaling in Human Medulloblastoma. Molecular Targets of CNS Tumors, Dr. Miklos Garami (Ed.), InTech. doi: 10.5772/23296. Available from: http://www.intechopen.com/books/molecular-targets-of-cns-tumors/the-role-ofhgf-c-met-pathway-signaling-in-human-medulloblastoma.
32. Butch ER, Guan K-L. Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. J Biol Chem. 1996; 271:4230-4235.
33. Roskoski R. MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem Bioph Res Co. 2012; 417:5-10.
34. Chang X, Firestone GL, Bjeldanes LF. Inhibition of growth factor-induced Ras signaling in vascular endothelial cells and angiogenesis by 3, 3'-diindolylmethane. Carcinogenesis. 2006; 27:541-550.
35. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmaco. 2008; 8:393-412.
36. Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_ AM.2013.33.e395. Review.
37. Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K. Clinical significance of MET in gastric cancer. World J Gastrointest Oncol. 2015; 7:317-327.
38. Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, Ge S, Shen L. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with metaanalysis. PLoS One. 2014; 9:e84502.
39. Gandino L, Longati P, Medico E, Prat M, Comoglio PM. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem. 1994; 269:1815-1820.
40. Nakayama M, Sakai K, Yamashita A, Nakamura T, Suzuki Y, Matsumoto K. Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes. Cytokine. 2013; 62:446-452.